Trevena Q2 2023 Earnings Report
Key Takeaways
Trevena reported net revenue of $3.0 million and a net loss attributable to common stockholders of $8.0 million, or $0.69 per share, for the second quarter of 2023. They anticipate a $15 million non-dilutive tranche from R-Bridge in Q3 2023.
Database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy announced; topline data expected 3Q 2023.
TRV045 proof-of-concept study evaluating potential for use in acute and chronic pain advancing with topline data expected 3Q 2023.
New respiratory data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3Q 2023.
OLINVYK-treated patients had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated with other IV opioids in the ARTEMIS study.